Biotech Fund Reveals $15 Million MoonLake Exit After Stock's 90% Crash

MPM BioImpact fully exited its MoonLake Immunotherapeutics stake in Q3, disposing of 313,571 shares for an estimated $14.8 million reduction that previously represented 2.6% of AUM, according to an SEC filing. MoonLake shares trade at $13.80 (down ~74% year-over-year) after a near-90% one-day collapse tied to mixed Phase 3 sonelokimab results and a resulting class-action suit; the company has $380.5 million cash, guidance projecting runway into H2 2027, and an FDA meeting scheduled for Dec. 15 to review its evidence package. The divestiture underscores risk-off positioning in high-volatility clinical-stage names and may keep downward pressure on sentiment absent positive regulatory or clinical catalysts.

Analysis

Market structure: MoonLake (MLTX) sell-off hands short-term advantage to large, incumbent immunology drug makers (e.g., ABBV, BMY) and deep-pocket acquirers that can buy assets cheaply; nanobody-platform peers face re-rating and higher financing costs. The immediate supply of tradable MLTX shares has not meaningfully changed, but demand plunged (share price -~74% YTD) which raises option implied volatility and widens credit spreads on any corporate paper; expect IV to remain elevated into the Dec 15 FDA meeting.

Risk assessment: Tail risks include (1) FDA deeming the evidence package inadequate leading to clinical program halt (low-probability, high-impact); (2) class-action damages or accelerated cash burn forcing dilutive financing; (3) a positive FDA interaction triggering a >100% rebound. Near-term (days) risk centers on headline volatility around Dec 15; short-term (weeks/months) on trial readouts/partnership moves; long-term (quarters) on commercialization/reimbursement dynamics and potential dilution beyond H2 2027 runway.

Trade implications: Use event-driven, size-limited positions: buy asymmetric call spreads to capture binary upside while selling premium or using put-spreads to cap downside. Prefer pair trades that short MLTX idiosyncrasy and go long large-cap immunology (ABBV) to collect yield and reduce event risk. Reduce small-cap clinical exposure and rotate ~4–6% NAV into cash-generative pharma and medtech until the regulatory path is clarified.

Contrarian angles: Consensus prices near-terminal failure but ignores $380M cash runway and an FDA meeting in ~17 days — if FDA signals a defined path, upside could be >2x from depressed levels; conversely, management may issue equity (dilution) which is underpriced in current market. Historical parallels: several clinical-stage biotechs have retraced 50–150% post-clarity; therefore options-based asymmetric bets around the FDA event are preferable to naked directional positions.

Key Decisions for Investors

• Establish a capped, event-driven long in MLTX: allocate 1.5% NAV to a Jan 2026 call spread (buy ~$16 call, sell ~$22 call, strikes ~15–60% above current $13.80) to obtain >2x upside if FDA/clinical clarity is positive; cut entirely if FDA feedback is explicitly 'insufficient' or cash runway <12 months.
• Hedge downside with a 1.0% NAV Jan 2026 put spread (buy 25% OTM put, sell 45% OTM put) to limit cost while protecting against a post-FDA >30% downside move; exit within 3 trading days of the FDA decision unless new data changes fundamentals.
• Implement a pair trade: go long ABBV (AbbVie) equal to 3.0% NAV financed by a 1.5% NAV short position in MLTX to capture idiosyncratic collapse while retaining exposure to immunology secular growth; rebalance if MLTX moves +/-50% pre-event.
• Reduce aggregate small-cap clinical-stage biotech exposure by 4–6% NAV and redeploy into large-cap, cash-generative healthcare (e.g., ABBV, JNJ) or defensive medtech over the next 10 trading days to lower portfolio IV and funding risk.